CDTX
Cidara Therapeutics, Inc.220.05
-0.05-0.02%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
6.92BP/E (TTM)
-Basic EPS (TTM)
-11.20Dividend Yield
0%Recent Filings
8-K
Merck acquires Cidara outright.
Cidara Therapeutics completed its acquisition by Merck Sharp & Dohme LLC on January 7, 2026, after 88.3% of shares tendered at $221.50 per common share and $15,505 per Series A share. The tender offer expired January 6; Cidara became Merck's wholly owned subsidiary. Nasdaq delisted shares immediately. All equity plans terminated.
8-K
Merck tenders for Cidara at $221.50/share
Cidara Therapeutics signed a merger agreement with Merck subsidiary on November 13, 2025, launching a tender offer by December 4 for common shares at $221.50 and Series A preferred at $15,505 in cash. Post-tender merger leaves Cidara as Merck's wholly owned unit, with options and RSUs cash-settled at premium. HSR clearance required; termination fees hit $300M one way, $462M reverse. Deal locks in big payout.
8-K
ANCHOR study advances rapidly
Cidara Therapeutics reported Q3 2025 results, highlighting Phase 3 ANCHOR study for CD388 influenza preventative now over 50% enrolled toward 6,000 participants by December 2025, triggering a $45.0 million Janssen milestone. Cash swelled to $476.5 million, funding the program fully, bolstered by a $58.1 million BARDA base award and FDA Breakthrough Therapy nod. ANCHOR expands to healthy adults over 65. Net loss hit $83.2 million amid ramped R&D.
10-Q
Q3 FY2025 results
Cidara Therapeutics posted a Q3 net loss of $83.2M, up from $16.0M y/y, driven by $45M acquired IPR&D for a Janssen milestone on ANCHOR Phase 3 dosing and $35.5M R&D (derived q/q up from prior quarters on manufacturing and trial prep). Cash swelled to $293.7M plus $176.5M investments on $377M public offering net proceeds, yielding $476.5M liquidity with no debt. BARDA inked a $58.1M base contract for CD388 onshoring and trials through Sept 2027, options up to $339M total. YTD net loss hit $132.4M on $85M R&D ramp. Clinical trial delays could stall progress.
8-K
BARDA awards Cidara $339M contract
Cidara Therapeutics inked a BARDA contract on September 30, 2025, unlocking up to $339.2 million for CD388's manufacturing onshoring and clinical trials through 2027, with $58.1 million base funding. Options could add $281.1 million, though Cidara covers up to $192.2 million cost share on three. BARDA can terminate with 60 days' notice. Funding bolsters influenza defenses.
ARCT
Arcturus Therapeutics Holdings
7.13-0.12
BCAX
Bicara Therapeutics Inc.
18.15-0.21
CCCC
C4 Therapeutics, Inc.
2.26-0.17
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
COCP
Cocrystal Pharma, Inc.
0.98-0.04
CYDY
CytoDyn Inc.
0.32+0.02
FATE
Fate Therapeutics, Inc.
1.09-0.03
TARA
Protara Therapeutics, Inc.
5.42-0.08
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
XRTX
XORTX Therapeutics Inc.
0.59-0.01